AZN$87.68
$88.08
Chart
Performance
Key Stats
AI AZN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAstraZeneca shows strong fundamental health with robust profitability and a solid balance sheet. It is well-positioned in key therapeutic areas, though current valuation metrics warrant consideration. Technicals indicate a mixed short-term outlook, with long-term indicators generally positive.
Thematic
AstraZeneca benefits from strong secular trends in biopharmaceuticals, including aging populations, advancements in oncology and rare diseases, and a focus on respiratory and immunology. The company's investment in innovative therapies and collaborations positions it well for future growth.
Fundamental
AstraZeneca demonstrates consistent revenue growth, improving profitability (especially net margins), and a healthy balance sheet with manageable debt levels. Free cash flow generation is robust, supporting operations and investments.
Technical
The stock is trading within its 52-week range but has shown mixed performance recently. While long-term trends appear stable, short-term indicators suggest some consolidation or potential for minor pullbacks, especially in lower timeframes.
| Factor | Score |
|---|---|
| Oncology Advancements | 90 |
| Rare Diseases & Specialty Care | 85 |
| Cardiovascular, Renal & Metabolism | 80 |
| Innovation & Partnerships | 70 |
| Emerging Markets Focus | 65 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 85 |
| Growth | 88 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Dividend Yield | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Support & Resistance (1D) | 65 |
| Short-term Oscillators (15m) | 50 |
| Volume | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprise
Recent quarterly EPS surprises have been largely positive, with the latest quarter (2025 Q2) showing a surprise of 16.67% (reported 1.3 vs. estimate 1.11).
Reasonable P/E Ratio
The trailing P/E ratio of 39.1 (TTM) is comparable to its historical performance and industry peers, suggesting it may not be excessively overvalued based on current earnings.
Bearish Points (7)
High P/S Ratio
The Price-to-Sales (P/S) ratio of 5.4 (TTM) appears high, especially when compared to the 2021 P/S of 4.5, suggesting the market may be pricing in significant future revenue growth.
Slowing Revenue Growth Trends
While annual revenue growth was strong in 2024 (54.07B) compared to 2023 (45.81B), quarterly revenue growth in Q4 2024 (14.89B) shows a lower net income margin (10.1%) compared to Q1 2025 (21.5%).
Calendar
February 2025
21
Ex-Dividend Date
March 2025
24
Next Dividend Date
July 2025
29
Next Earnings Date
H: $1.12
A: $1.10
L: $1.07
H: 14.45B
A: 14.10B
L: 13.63B
Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Seasonals
Price Target
85.27 USD
The 39 analysts offering 1 year price forecasts for AZN have a max estimate of 102.00 and a min estimate of 67.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in oncology, immunology, and diagnostics, with a strong focus on innovative biopharmaceuticals.
Weight: 95
Major global pharmaceutical competitor with a diverse portfolio including oncology, inflammation, and rare diseases, overlapping significantly with AZN's therapeutic areas.
Weight: 93
Strong direct competitor in oncology, especially with its flagship Keytruda, and also in vaccines and hospital products.
Weight: 92
Significant competitor in oncology (Opdivo), immunology, and cardiovascular diseases, key therapeutic areas for AZN.